Compliance Certificate For The Half Year Ended 31St March, 2018
With respect to the subject cited above, please find the attached Certificate issued under Reg.40 (9) of SEBI (LODR) Regulations, 2015, by M/s. P.S. Rao & Associates, Company Secretaries, for the half year ended 31st March, 2018. Kindly take the same on record. Announcement Under Regulation 30 (LODR)-EU-GMP Certification Received From Austrian Agency, AGES
This is to inform you that the Company has received EU-GMP certification from Austrian Agency, AGES for its two API Manufacturing Plants located at Raichur, Karnataka and Formulation Facility located at Jadcherla, Telangana. Austrian Agency, AGES carried out audit of said API plants between January 16th and January 24th, 2018 and Formulation Facility between January 25th and January 31st, 2018. This is for your information and record. Shareholding for the Period Ended March 31, 2018
Shilpa Medicare Ltd has submitted to BSE the Shareholding Pattern for the Period Ended March 31, 2018. For more details, kindly Click here Statement Of Investor Complaints For The Quarter Ended March 2018
No.of Investor complaints pending at the beginning of the quarter No.of Investor complaints received during the quarter No.of Investor complaints disposed of during the quarter No.of Investor complaints unresolved at the end of the quarter 0660 Name of the Signatory :- MADHUSUDHAN REDDYDesignation :- Company Secretary and Compliance Officer Announcement under Regulation 30 (LODR)-Meeting Updates
We hereby inform you that the Board of Directors at their meeting held today, has decided to dispose off all the shares held by the Company in the Joint Venture Company, Raichem Medicare Limited to other Joint Venture Partner M/s. ICE S.p.A Italy on the mutually agreed terms and conditions. The Meeting was commenced at 05:30 P.M and ended at 08.10 P.M.... Shilpa Medicare climbs 7% on receiving EIR
The facility was inspected between November 11 and November 30, 2017. Rectification Of Intimation Filed Under Regulation 30 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015 Dated 16.03.2018. :EIR Received From USFDA For Our Formulation Unit At Jadcherla, Telangana
This is to inform you that the US FDA has issued an Establishment Inspection Report (EIR) for our Company's formulations manufacturing facility (SEZ unit) located at Jadcherla, Telangana, India which was inspected between 11th November and 30th November 2017. FDA has determined that the inspection classification of this facility is VAI and accordingly EIR issued.... Announcement Under Regulation 30 (LODR) - Updates
This is to inform you that the US FDA intimated the Company that based on its inspection from 11th November to 30th November 2017 the Unit of the Company located at S-20 TO S-24/A, pharmaceutical Formulations SEZ TSIIC, Green Industrial Park, Polepally, Jadcherla, Mahabubnagar, Telangana, India, has been determined that the inspection classification of this facility is VAI.... Disclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations, 2011
The Exchange has received the disclosure under Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Brijgopal Inani Disclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations, 2011
The Exchange has received the disclosure under Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Ramakant Inani